084650 — Labgenomics Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapSucker Stock

Annual cashflow statement for Labgenomics Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	83,855	47,926	-5,246	-23,904	-64,375
Depreciation
Amortisation
Non-Cash Items	21,329	20,113	1,520	7,503	52,254
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-42,443	-2,136	252	-6,193	-28,727
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	66,081	69,869	2,422	-12,995	-30,536
Capital Expenditures	-13,815	-38,330	-5,196	-4,547	-1,663
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-12,246	-14,988	-111,408	786	16,704
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-26,061	-53,317	-116,604	-3,762	15,041
Financing Cash Flow Items	0	—	-72.7	47.1	3
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-7,194	11,445	57,646	-2,229	-2,065
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	32,694	27,982	-56,186	-17,814	-17,748